Citi analyst Paul Lejuez lowered the firm’s price target on Bath & Body Works to $21 from $35 and keeps a Buy rating on the shares post the Q3 report. The firm says the company’s outlook for Q4 is “much worse” than expectations. However, following the post-earnings selloff, Citi finds the stock’s risk/reward as favorable.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBWI:
- Bath & Body downgraded to Market Perform from Outperform at Telsey Advisory
- Bath & Body Works price target lowered to $18 from $28 at Barclays
- Challenges Ahead: Bath & Body Works Faces Structural Headwinds and Downgrade
- Bath & Body Works downgraded to Equal Weight from Overweight at Morgan Stanley
- Bath & Body Works Unveils Strategic Growth Plan